Wenkai Wang

Wenkai Wang

Auto-generated profile, based on publicly available information

Wenkai Wang

Department of Orthopedics, Xinqiao Hospital, Third Military Medical University (Army Medical University), Chongqing, China

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
WWWenkai Wang
Wenkai Wang
ZCZhuo Cheng
Zhuo Cheng
MYMiao Yu
Miao Yu
KLKe Liu
Ke Liu
HDHongli Duan
Hongli Duan
MLMinghan Liu
Minghan Liu
Discectomy-induced ferroptosis of nucleus pulposus cells (NPCs) contributes to postoperative lumbar disc herniation (LDH) recurrence and intervertebral disc degeneration (IDD). We discover that nucleus pulposus progenitor cells (NPPCs) could imprint ferroptosis resistance into NPCs through exosome-dependent intercellular transmission of miR-221-3p. Based on these findings, we first develop synthetically-tailored NPPC-derived exosomes with enhanced miR-221-3p expression and NPC uptake capacity, which are integrated into an injectable hydrogel based on extracellular matrix (ECM) analogues. The ECM-mimetic hydrogel (HACS) serves as a biomimetic filler for the post-operative care of herniated discs, which could be facilely injected into the discectomy-established nucleus pulposus (NP) cavity for localized treatment. HACS-mediated in-situ exosome release in the NP cavity enables marked ferroptosis inhibition in NPCs that not only prevents LDH recurrence but also reverses the IDD symptoms, leading to robust restoration of NP structure and functions. In summary, this study offers a promising approach for treating disc herniation.

1 May 2020 in Acta Biomaterialia
Verified
Journal Article
Closed access
WWWenkai Wang
Wenkai Wang
RZRui Zuo
Rui Zuo
HLHaixia Long
Haixia Long
YWYanqiu Wang
Yanqiu Wang
YZYang Zhang
Yang Zhang
JLJie Li
Jie Li

1 August 2019 in Clinical Neurology and Neurosurgery
Verified
Journal Article
Closed access
WWWenkai Wang
Wenkai Wang
CLChao Liu
Chao Liu
JLJie Li
Jie Li
HLHaiyin Li
Haiyin Li
JWJunlong Wu
Junlong Wu
YZYue Zhou
Yue Zhou

27 July 2022 in Molecular Microbiology
Verified
Journal Article
Closed access
PLPeiwen Lv
Peiwen Lv
YLYaru Li
Yaru Li
RWRuimin Wang
Ruimin Wang
YZYe Zhang
Ye Zhang
WWWenkai Wang
Wenkai Wang
CYChunyu Yang
Chunyu Yang

24 December 2024 in Advanced Science
Verified
Journal Article
Open access
WWWenkai Wang
Wenkai Wang
YWYan Wang
Yan Wang
XHXinle Huang
Xinle Huang
PWPeng Wu
Peng Wu
LLLanlan Li
Lanlan Li
JZJianxiang Zhang
Jianxiang Zhang
Neuropathic pain, one of the most refractory pain diseases, remains a formidable medical challenge. There is still an unmet demand for effective and safe therapies to address this condition. Herein, a rat model of nerve injury‐induced neuropathic pain is first established to explore its pathophysiological characteristics. Recognizing the role of neuroinflammation, an inflammation‐resolving amphiphilic conjugate PPT is designed and synthesized by simultaneously conjugating polyethylene glycol, phenylboronic acid pinacol ester, and Tempol onto a cyclic scaffold. PPT can self‐assemble into nanomicelles (termed PPTN). Following intravenous injection, PPTN preferentially accumulates in the injured nerve, ameliorates the neuroinflammatory milieu, and promotes nerve regeneration, thereby shortening neuropathic pain duration in rats. Moreover, the Ca2+ channel α2δ1 subunit is identified as a therapeutic target by RNA‐sequencing analysis of the injured nerve. Based on this target, a mimicking peptide (AD peptide) is screened as an analgesic. By packaging AD peptide into PPTN, a combination nano‐analgesic APTN is developed. Besides potentiated anti‐hyperalgesic effects due to site‐specific delivery and on‐demand release of AD peptide at target sites, APTN simultaneously inhibits neuroinflammation and promotes nerve regeneration by reprogramming macrophages via regulating MAPK/NF‐kB signaling pathways and NLRP3 inflammasome activation, thus affording synergistic efficacies in treating nerve injury‐induced neuropathic pain.